Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Phase one

<< Previous

Bullboard Posts

Next >>

Comment by bud13on Mar 25, 2022 9:55pm

41 Views

Post# 34547525

RE:RE:Phase one

don't worry Red, I have made a few trade's to get er back over time and still have the same base. How about you? That's the interesting question eh. Can you answer this question to the point and honest? Well? No roundabout bushes in my yard Red! So!

<< Previous

Bullboard Posts

Next >>

One of the strongest contenders to lead Canada’s cannabis market